Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8726MR)

This product GTTS-WQ8726MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8726MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15826MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ5923MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ3892MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ11208MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ6189MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ6906MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3719MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ14097MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-421
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW